Dr. Zhenbin Ding 丁振斌
Chief Physician
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision and minimally invasive surgery for liver and biliary tract tumors. Comprehensive treatment of metastatic liver cancer, especially colorectal liver metastases. Liver transplantation and living donor liver transplantation.
Dr. Ding holds a PhD and serves as Chief Physician in the Liver Surgery Department at Zhongshan Hospital, Fudan University, and as a master’s supervisor. Dr. Ding performs nearly 300 liver cancer resections and over 30 liver transplants annually, focusing on minimally invasive resection, ALPPS, and living donor liver transplantation. Dr. Ding trained in living donor liver transplantation at Kaohsiung Chang Gung Memorial Hospital.
Professional roles
- Group Leader, Professional Group, Chinese Medical Association
- Deputy Head, Youth Group, Oncology Branch, Chinese Medical Association
- Vice Chair, Youth Committee, Oncology Branch, Shanghai Medical Association
- Member, Liver Surgery Group, General Surgery Branch, Shanghai Medical Association
Name order: in Chinese the family name comes first (Ding Zhenbin). Papers usually list the name as Zhenbin Ding or Ding Z.
Selected publications
110 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Sci, 2026 (senior author): Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING-Mediated Type I Interferon Response in iCCA. PubMed 42227200
- J Immunother Cancer, 2026 (senior author): UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma. PubMed 42419879
- Exp Hematol Oncol, 2026 (senior author): Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma. PubMed 42304527
- World J Gastrointest Surg, 2025 (senior author): Laparoscopic hepatectomy using indocyanine green attenuates postoperative inflammatory response for hepatocellular carcinoma: A propensity score matching analysis. PubMed 39872757
- Int J Biol Macromol, 2024 (senior author): Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation. PubMed 39074701
- Hlife, 2024 (first author): Recent advances in surgical management strategies for hepatocellular carcinoma. PubMed 42903478
- Int Immunopharmacol, 2023 (senior author): Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma. PubMed 37494837
- Front Oncol, 2023 (senior author): Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6(+) CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma. PubMed 37593098
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion